Reuters -- A U.S. medical advisory panel unanimously urged U.S. approval of Recordati SpA’s (RECI.MI) proposed drug for a rare blood condition, saying it could help turn the potentially fatal disorder into a livable, chronic condition.
Reuters -- A U.S. medical advisory panel unanimously urged U.S. approval of Recordati SpA’s (RECI.MI) proposed drug for a rare blood condition, saying it could help turn the potentially fatal disorder into a livable, chronic condition.
